Springer Amends Cartesian Therapeutics Stake

TL;DR

Springer updated his Cartesian Therapeutics filing. Watch for more details.

AI Summary

Timothy A. Springer, through TAS Partners LLC, has amended their Schedule 13D filing for Cartesian Therapeutics, Inc. on November 18, 2024. The filing indicates a change in beneficial ownership, though specific new holdings or dollar amounts are not detailed in this excerpt. The amendment pertains to common stock of Cartesian Therapeutics, Inc.

Why It Matters

Changes in significant shareholder filings like this can signal shifts in control or investment strategy, potentially impacting the stock price of Cartesian Therapeutics.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D often indicate significant changes in a major shareholder's position, which can lead to increased stock volatility.

Key Numbers

• 20241118 — Filing Date (Date of the Schedule 13D/A amendment)

Key Players & Entities

• Cartesian Therapeutics, Inc. (company) — Subject Company
• Timothy A. Springer (person) — Filing Person
• TAS Partners LLC (company) — Group Member/Affiliate of Filing Person
• Michael K. Bradshaw, Jr. (person) — Authorized to Receive Notices
• Nelson Mullins Riley & Scarborough LLP (company) — Legal Counsel

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
• $15.65 — of 96,399 Shares at prices ranging from $15.65 to $17.00 per share for an aggregate pu
• $17.00 — Shares at prices ranging from $15.65 to $17.00 per share for an aggregate purchase pri
• $1,578,156 — gregate purchase price of approximately $1,578,156. Dr. Springer used personal funds for s
• $16.61 — f 277,246 Shares at prices ranging from $16.61 to $17.25 per share for an aggregate pu
• $17.25 — Shares at prices ranging from $16.61 to $17.25 per share for an aggregate purchase pri
• $4,739,186 — gregate purchase price of approximately $4,739,186. Dr. Springer used personal funds for s
• $17.32 — of 58,295 Shares at prices ranging from $17.32 to $18.50 per share for an aggregate pu
• $18.50 — Shares at prices ranging from $17.32 to $18.50 per share for an aggregate purchase pri
• $1,056,183 — gregate purchase price of approximately $1,056,183. Dr. Springer used personal funds for s

Filing Documents

• ea0221734-13da17spring_cart.htm (SC 13D/A) — 78KB
• 0001213900-24-099811.txt ( ) — 80KB

Source

Item 3. Source and Amount of Funds or Other Consideration .

of the Schedule 13D is hereby amended to be supplemented by

Item 3 of the Schedule 13D is hereby amended to be supplemented by the following: In open market purchases on November 14, 2024, Dr. Springer acquired an aggregate of 96,399 Shares at prices ranging from $15.65 to $17.00 per share for an aggregate purchase price of approximately $1,578,156. Dr. Springer used personal funds for such acquisitions. In open market purchases on November 15, 2024, Dr. Springer acquired an aggregate of 277,246 Shares at prices ranging from $16.61 to $17.25 per share for an aggregate purchase price of approximately $4,739,186. Dr. Springer used personal funds for such acquisitions. In open market purchases on November 18, 2024, Dr. Springer acquired an aggregate of 58,295 Shares at prices ranging from $17.32 to $18.50 per share for an aggregate purchase price of approximately $1,056,183. Dr. Springer used personal funds for such acquisitions. CUSIP No . 816212302 13D Page 6 of 7 Pages Item 5. Interest in Securities of the Issuer .

of Schedule 13D is hereby amended and restated in full as follows

Item 5 of Schedule 13D is hereby amended and restated in full as follows: The information set forth under Item 3 and the cover page of the Schedule 13D is incorporated herein by reference into this Item 5. (a) The percentages of beneficial ownership reported in this Item 5, and on each Reporting Person’s cover page to this Statement, are based on a total of 25,414,898 Shares issued and outstanding as of November 1, 2024, as reported on the Issuer’s Quarterly Report on Form 10-Q, dated November 7, 2024. All of the Share numbers reported below, and on each Reporting Person’s cover page to this Statement, are as of November 18, 2024. The Reporting Persons, in the aggregate, beneficially own 9,481,816 Shares, representing approximately 37.1% of such class of securities. Dr. Springer is the beneficial owner of a total of 9,481,816 Shares, representing approximately 37.1% of the outstanding Shares and consisting of (i) 8,449,773 Shares held directly, (ii) 113,587 Shares underlying warrants exercisable within 60 days of November 18, 2024 held directly, (iii) 2,533 Shares issuable upon exercise of outstanding options exercisable within 60 days of November 18, 2024, (iv) 1,977 Shares underlying RSUs vesting within 60 days of November 18, 2024, (v) 529,798 Shares held by TAS, (vi) 33,408 Shares underlying warrants exercisable within 60 days of November 18, 2024 held by TAS, (vii) 330,695 Shares held by Dr. Lu and (viii) 20,045 Shares underlying warrants exercisable within 60 days of November 18, 2024 held by Dr. Lu. TAS is the beneficial owner of a total of 563,206 Shares, representing approximately 2.2% of the outstanding Shares and consisting of (i) 529,798 Shares and (ii) 33,408 Shares underlying warrants exercisable within 60 days of November 18, 2024. TAS holds all such Shares directly. Dr. Springer is the sole managing member of TAS. Dr. Lu is the beneficial owner of a total of 350,740 Shares, representing approximately 1.4% of the outstanding Sh

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 18, 2024 /s/ Timothy A. Springer Timothy A. Springer /s/ Chafen Lu Chafen Lu TAS Partners LLC By: /s/ Timothy A. Springer Name: Timothy A. Springer Title: Manager

View Full Filing

View this SC 13D/A filing on SEC EDGAR